Advertisement
Screener

Onconetix, Inc. (ONCO) Deferred Costs, Current

2.8 / 5 stars · 68/120 Roast Me

Onconetix, Inc. Deferred Costs, Current

Onconetix, Inc. (ONCO) had Deferred Costs, Current of $366.11 thousand as of 2023-03-31, per its 10-Q filed 2023-05-12.

Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current

us-gaap:DeferredCostsCurrent · last filed 2023-05-12

  • 2023-03-31: Deferred Costs, Current $366.11K.
  • 2022-09-30: Deferred Costs, Current $176.30K.
  • 2022-06-30: Deferred Costs, Current $238.80K.
  • 2022-03-31: Deferred Costs, Current $238.80K.
Period endDeferred Costs, Current
2023-03-31$366.11K
10-Q · filed 2023-05-12
2022-09-30$176.30K
10-Q · filed 2022-11-14
2022-06-30$238.80K
10-Q · filed 2022-08-15
2022-03-31$238.80K
10-Q · filed 2022-05-13
2021-12-31$757.65K
10-K · filed 2023-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
Aptevo Therapeutics Inc. (APVO)United States$0.003B
Sunshine Biopharma Inc. (SBFM)$0.003B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
Genprex, Inc. (GNPX)United States$0.003B-0.02
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90